newsfilter
← Latest News
GlobeNewswire·

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Bicara Therapeutics announced substantial enrollment in the FORTIFI-HN01 pivotal trial for 1L R/M HPV-negative HNSCC, with interim analysis topline results expected in mid-2027.
  • The company is enrolling the FORTIFI-FLEX alternate dosing study to evaluate a loading dose followed by every-three-week maintenance dosing, with data expected by the time of potential U.S. approval.
  • Third-quarter 2026 cash, cash equivalents, & marketable securities totaled $442.3 million, providing funding for operations into the first half of 2029.
  • Research and development expenses rose to $56.5 million in Q3 2026 from $33.0 million in Q3 2025, driven by trial costs & personnel increases.
  • General and administrative expenses increased to $19.2 million in Q3 2026 from $7.7 million in Q3 2025 due to expanded personnel & professional fees.
  • Net loss for Q3 2026 was $71.2 million, compared to $36.3 million in Q3 2025.
  • Upcoming milestones include presenting Phase 1b mCRC data in January 2027 & preclinical TGF-β fibrosis data at the ESMO Immuno-Oncology Congress in December 2026.
  • Bicara will host a conference call on November 9, 2026, at 8:30 a.m. ET to discuss financial results & business updates.
Company
Bicara Therapeutics Inc.
Keywords
Nasdaq:BCAX, Bicara Therapeutics Inc.